• Novartis signs billion-dollar biobuck deal with Argo in Shanghai. • Deal focuses on siRNA medicines development. • Novartis continues strategic investments in RNA-based therapies. Novartis signs a billion-dollar biobuck deal with Shanghai-based biotech company Argo, marking one of the largest agreements of its kind this year. The Swiss pharmaceutical giant is investing heavily in the development of small interfering RNA (siRNA) medicines, a promising area in the treatment of various diseases. This agreement follows a similar commitment made just a day earlier, highlighting Novartis’s strategic focus on RNA-based therapies. The financial terms of the deal include billions in potential…
Author: PharmaSignal News Desk
Amgen to build $600m science and innovation centre in the US
European Parliament’s SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
Atlas Venture, one of the mainstay biotech venture capital firms, has collected its second batch of money within the past nine months.
Remedy Meds is buying Thirty Madison, a virtual care startup that competes with the likes of Hims and Ro.
Remedy Meds, which sells GLP-1 weight loss medications and provides telehealth services directly to consumers, will ….
Deal includes global rights to cancer therapies. $200M upfront payment by Servier to Ideaya.
A biotech co-founded by Nobel laureate David Baker has reeled in an $80 million Series B to get into the clinic early next year with an AI-designed cancer drug.
Alnylam Pharmaceuticals said it will start a Phase 3 cardiovascular outcomes trial of its hypertension therapy zilebesiran this year, despite data showing the drug failed in a mid-stage study.
The end of Covid vaccine emergency authorizations may limit the availability of shots for young, healthy kids.
AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major depression